RT Journal Article
T1 Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.
A1 Gelincik, Aslı
A1 Brockow, Knut
A1 Çelik, Gülfem E
A1 Doña, Inmaculada
A1 Mayorga, Cristobalina
A1 Romano, Antonino
A1 Soyer, Ozge
A1 Atanaskovic-Markovic, Marina
A1 Barbaud, Annick
A1 Torres, Maria Jose
K1 COVID-19
K1 SARS-CoV-2
K1 Desensitization
K1 Drug hypersensitivity reactions
AB Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.
PB Wiley
YR 2020
FD 2020-06-01
LK http://hdl.handle.net/10668/15697
UL http://hdl.handle.net/10668/15697
LA en
NO Gelincik A, Brockow K, Çelik GE, Doña I, Mayorga C, Romano A, et al. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. Allergy. 2020 Nov;75(11):2775-2793
DS RISalud
RD Apr 8, 2025